GLP-1 'microdosing' for weight loss lacks evidence—what Canadian patients should know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

GLP-1 receptor agonist 'microdosing'—using fractions of the standard therapeutic dose of drugs like semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for chronic weight management) or tirzepatide (sold in Canada as Mounjaro for type 2 diabetes and Zepbound, not yet authorized by Health Canada for weight management as of May 2026)—has no clinical trial evidence supporting its use for weight loss, according to a May 29, 2026 opinion piece in STAT News by Dr. Jody Dushay, an endocrinologist and assistant professor of medicine at Harvard Medical School. For Canadians, the implications are direct: Health Canada has not authorized any GLP-1 product at sub-therapeutic or 'micro' doses for any indication, and no Canadian clinical guideline from Obesity Canada or any other national body endorses the practice.

The trend is spreading north. Canadian patients are encountering microdosing claims through social media, US-based wellness platforms, and compounding pharmacies. Some Canadian telehealth services—including platforms like Felix, Maple, and Science & Humans (scienceandhumans.com)—offer GLP-1 prescribing, but these services are bound by Health Canada's authorized indications and standard dosing protocols. US-only platforms such as Hone Health, Midi, and Winona do not serve Canadian patients and are not subject to Health Canada oversight.

What this means in Canada

Health Canada has authorized semaglutide under two brand names: Ozempic (0.5 mg, 1 mg, and 2 mg weekly injections) for adults with type 2 diabetes, and Wegovy (escalating to 2.4 mg weekly) for adults with obesity or overweight with at least one weight-related comorbidity. Tirzepatide is authorized as Mounjaro for type 2 diabetes; a separate weight-management indication (equivalent to US-approved Zepbound) had not received Health Canada authorization as of this article's publication date. Neither drug has an authorized 'microdose' formulation or indication.

Provincial drug coverage reflects these authorized uses. In Ontario, OHIP+ and the Ontario Drug Benefit program cover Ozempic for eligible patients with type 2 diabetes; Wegovy coverage under provincial formularies remains limited and inconsistent across provinces. In Quebec, the Régie de l'assurance maladie du Québec (RAMQ) lists Ozempic for diabetes but does not cover Wegovy for weight management on the general formulary. British Columbia's PharmaCare and Alberta's Alberta Health Care Insurance Plan (AHCIP) follow similar patterns. No provincial formulary covers GLP-1 drugs at microdoses, because no such indication exists.

Obesity Canada, the national clinical organization that publishes Canadian obesity management guidelines, recommends GLP-1 therapies only at evidence-based therapeutic doses and within a comprehensive obesity management framework. The organization has not issued a position statement on microdosing specifically, but its 2020 Canadian Adult Obesity Clinical Practice Guidelines—the most recent comprehensive version—emphasize that pharmacotherapy should follow approved dosing regimens supported by randomized controlled trial data.

What changed

GLP-1 microdosing is not a new drug or a new formulation. It is a repurposing trend: patients and some prescribers are deliberately using doses far below those studied in clinical trials—sometimes as low as one-tenth of the standard starting dose—with the stated goals of reducing side effects, extending drug supply, or achieving modest weight loss without committing to full therapeutic doses. The term has no agreed clinical definition. In her STAT News piece, Dr. Dushay notes that 'there isn't even a single definition of microdosing for weight loss or any other condition,' making it impossible to evaluate safety or efficacy in any systematic way.

The trend has been amplified by ongoing shortages of semaglutide and tirzepatide in both the US and Canada, which have pushed some patients toward compounding pharmacies. In Canada, compounded semaglutide occupies a regulatory grey zone: Health Canada does not authorize compounded copies of approved drugs except under specific shortage conditions, and the safety and sterility of compounded GLP-1 products are not guaranteed by the same standards applied to manufacturer-produced drugs.

The clinical trials that established GLP-1 efficacy—including the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide—used specific escalating dose protocols over 68 weeks or longer, with thousands of participants. No equivalent trial has tested microdoses. Without that data, clinicians cannot tell patients what weight loss to expect, what side effects to anticipate, or whether any cardiovascular or metabolic benefits seen at full doses carry over.

What Canadian patients should know

If you are considering GLP-1 therapy for weight management, the starting point is a conversation with a physician or nurse practitioner who can assess whether you meet Health Canada's authorized criteria—typically a body mass index of 30 or above, or 27 or above with a weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea. Canadian telehealth platforms that prescribe GLP-1 medications are required to follow these criteria.

Patients who are already on a full therapeutic dose and experiencing side effects should discuss dose adjustments with their prescriber—there is some clinical flexibility in the escalation schedule—but this is different from deliberately staying at a sub-therapeutic dose indefinitely without a clinical rationale.

Be cautious about compounded GLP-1 products marketed online, including those shipped from US compounding pharmacies. These products are not reviewed by Health Canada for safety, efficacy, or quality. Importing unapproved drugs for personal use carries legal and health risks.

Provincial differences matter for access. If cost is a barrier to authorized GLP-1 therapy, ask your provider about provincial exceptional access programs, employer drug benefits, or manufacturer patient-support programs such as the Novo Nordisk Canada patient assistance program for Wegovy.

Limitations and open questions

The STAT News piece that prompted this article is an opinion column, not a peer-reviewed study. Dr. Dushay's clinical concerns are consistent with the absence of published trial data, but the piece does not itself constitute new evidence—it is an expert's interpretation of a gap in the literature.

It is possible that future research could identify a sub-therapeutic dose range with a meaningful benefit-to-risk profile for specific patient populations. Some researchers have proposed that lower doses might suit patients who need modest weight loss and cannot tolerate standard doses. That hypothesis has not been tested in adequately powered trials.

Health Canada has not issued specific guidance on microdosing, and Obesity Canada has not published a position statement on the practice. The CMAJ (Canadian Medical Association Journal) has not published a clinical review of GLP-1 microdosing as of this article's date. Until that evidence and regulatory clarity exist, Canadian clinicians have no evidence-based framework for offering or refusing microdose prescriptions—which means patients are navigating this largely on their own.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.